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Abstract
Introduction Peripherally localized aromatase, which converts
circulating androgens into estrogens, is important in the
pathogenesis of postmenopausal breast carcinomas. We have
previously shown that aromatase mRNA levels are higher in
elderly breast carcinomas (EldCa) than breast carcinomas of the
control group (ContCa) or normal breast tissues. Aromatase
expression has been reported to be regulated through the
alternative use of multiple exons 1 (exons 1a-1f and so on);
however, the preferential usage of exons 1 in elderly breast
tissue has never been systematically examined. In order to
properly treat and protect against EldCa, the regulation
mechanism of aromatase expression in elderly breast tissues
should be elucidated. The aim of the present study is to
elucidate whether there are any specific patterns in use of
multiple exons 1 in elderly breast tissue.
Methods Usage of multiple exons 1 of the aromatase gene and
mRNA levels of aromatase were examined by reverse
transcription-polymerase chain reaction analysis in breast
tissues of 38 elderly patients with breast cancer (age 80–99),
and the results were compared with those in 35 patients of the
control group (age 37–70). One-factor analysis of variance and
the Scheffé test were used for the comparison of aromatase
mRNA levels. Patterns of preferential utilization of multiple exons
1 of the aromatase gene were compared by χ2  test for
independence or Fisher exact test for independence using a
contingency table.
Results Exon 1d was utilized much more frequently in elderly
tissue than in the control group irrespective of cancerous or
normal tissue (EldCa, 36/38, 95% versus ContCa, 7/35, 20%,
P < 0.0001; normal tissue of the elderly, EldNorm, 30/34, 88%
versus normal tissue of controls, ContNorm, 2/29, 7%, P  <
0.0001). Twenty EldCa (53%) and 12 EldNorm (35%) used
both exons 1c and 1d; however, their dominance was reversed
(EldCa, all 1d > 1c; EldNorm, all 1c > 1d).
Conclusions Elderly breast tissues exhibited specific patterns
in use of multiple exons 1, which at least partly explained the
higher aromatase levels in EldCa. The mechanisms of how these
specific patterns occur during aging and carcinogenesis should
be further examined.
Introduction
Estrogen plays important roles in the pathogenesis and devel-
opment of breast cancer [1]. In postmenopausal women, in
whom ovarian function has decreased, the peripheral metabo-
lism and biosynthesis of estrogens via estrogen-metabolizing
enzymes are important. Among several estrogen-metabolizing
enzymes involved in the pathogenesis of breast cancer [2-10],
aromatase is a key enzyme, converting circulating androgens
ANOVA: analysis of variance; ContCa: carcinomas from controls; ContNorm: normal tissues from controls; COUP-TF-1: chicken ovalbumin upstream 
promoter-transcription factor 1; COX-2: cyclooxygenase-2; CRE: cAMP-responsive element; EldCa: carcinomas from the elderly; EldNorm: normal 
tissues from the elderly; ER: estrogen receptor; Ex 1: multiple exons 1 of the aromatase gene; PCR: polymerase chain reaction; PGE2: prostaglandin 
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from the adrenal gland or ovary into estrogens [2]. The appli-
cation of aromatase inhibitors is already a standardized treat-
ment for postmenopausal breast carcinomas [11-14].
Physiologically, aromatase exists not only in gonadal tissues
such as the ovary and placenta, but also in extragonadal tis-
sues such as the brain [15], skin fibroblasts [16], and adipose
tissue [17]. The tissue-specific expression of aromatase is
strictly regulated; however, it is difficult to explain the complex
transcriptional regulation of the aromatase gene in various tis-
sues by a single gene and a single promoter. Multiple tissue-
specific promoters of the aromatase gene were first shown by
Means and colleagues [18] and Mahendroo and colleagues
[19]. We reported that the aromatase gene was regulated tis-
sue-specifically through the alternative use of multiple exons 1
[20]. Exons 1a (I.1), 1b (I.4), 1c (I.3), and 1d (P.II) are used
mainly for aromatase mRNAs of the placenta, skin fibroblast/
fetal liver, ovary, and prostate/ovary, respectively. Each of the
multiple exons 1 of the human aromatase gene is flanked by a
unique promoter region [21]. In regard to breast carcinogene-
sis, switching of the preferential utilization of multiple exons 1,
exon 1b to exon 1c/1d, has been suggested to be responsible
for the abnormal expression of aromatase and consequent
overproduction of local estrogen in tumors [22,23].
Breast carcinoma in very elderly women is of interest because
ovarian estrogens are markedly low throughout the disease
process. A previous study revealed that breast carcinoma in
very elderly women exhibits a distinct histologic pattern and
hormone receptor status [24]. We have examined mRNA lev-
els of several estrogen-metabolizing enzymes and have shown
that levels of aromatase mRNA were significantly higher in
breast carcinomas from women over the age of 80 years than
in carcinomas from younger women or in normal breast tissues
[25]. These findings suggest that breast carcinomas in very
elderly women are quite different from those in younger
women in terms of aromatase expression. As aromatase
expression is regulated by multiple exons 1 of the aromatase
gene, this should be elucidated in order to provide proper
treatment or protect against breast carcinomas in very elderly
women. In the present study, we investigate the preferential
utilization of multiple exons 1 of the aromatase gene, which
has never been systematically examined in breast carcinomas
or normal tissues of the elderly, and compare it with that in
breast tissues from younger women.
Materials and methods
Patients
Materials for this study were obtained from 38 Japanese
patients over the age of 80 (range 80 to 99 and mean 86)
years and 35 Japanese patients ages 37 to 70 (mean 53)
years with primary breast carcinomas who underwent curative
surgery at the Tokyo Metropolitan Geriatric Medical Center
and Fujita Health University Hospital, respectively, between
1999 and 2003. All tumors were histologically classified by
pathologists (NHo, KT, and GS) according to the World
Health Organization classification [26]. Of the 38 carcinomas
of the elderly, 24, 7, 5, and 2 were classified as invasive ductal
carcinoma, apocrine carcinoma, mucinous carcinoma, and
invasive lobular carcinoma, respectively, whereas all 35 carci-
nomas of the younger group were classified as invasive ductal
carcinoma. Immediately after surgical removal, the specimens
of both tumor tissues and normal tissues were frozen in liquid
nitrogen and then stored at -80°C prior to use. Normal breast
tissues were available in 34 elderly and 29 control cases.
Materials were classified into four tissue categories: carcino-
mas from the elderly (EldCa), normal tissues from the elderly
(EldNorm), carcinomas from controls (ContCa), and normal
tissues from controls (ContNorm). Informed consent was
obtained, and the study protocol was approved by the Tokyo
Metropolitan Institute of Gerontology Ethics Committee.
Quantification of aromatase mRNA
Frozen tissues were homogenized as previously reported [7],
and total RNA fractions were prepared from homogenates as
described by Chirgwin and colleagues [27]. Quantitative anal-
ysis of aromatase mRNA in RNA fractions was carried out by
reverse transcription-polymerase chain reaction (RT-PCR)
using a fluorescent primer in the presence of an internal stand-
ard RNA, as previously described [28,29]. Oligonucleotides of
antisense primer 6a (5'-AACCACGATAGCACTTTCGT-3'
specific for exon 6) for RT and antisense (5'-TGTTAGAGGT-
GTCCAGCATG-3' specific for exon 6) and sense (5'-TACTA-
CAACCGGGTATATGG-3' specific for exon 3) primers 6b
and 3a for PCR were synthesized. The sense primer 3a for
PCR was labeled with a fluorescent dye, 6-carboxyfluorescein
(PerkinElmer, Waltham, MA, USA). To prepare the internal
standard RNA, modified human aromatase cDNA was con-
structed by inserting a 21-base pair DNA fragment between
the two PCR primer sites. The internal standard RNA was syn-
thesized in vitro with T7 RNA polymerase using modified aro-
matase cDNA as a template. Total RNA mixed with a known
amount of internal standard RNA was subjected to RT with
SuperScript II RNase H- Reverse Transcriptase (Invitrogen
Corporation, Carlsbad, CA, USA) and specific antisense
primer 6a at 42°C for 40 minutes. The resulting cDNAs were
amplified by PCR using fluorescence-labeled primers 3a and
6b. The fluorescent PCR products were electrophoresed in a
2% agarose gel and analyzed with an ABI PRISM 377 DNA
Sequencer (Applied Biosystems, Foster City, CA, USA). The
amount of aromatase mRNA was calculated from the peak
areas of fluorescent products by the internal standard method.
Analysis of alternative usage of exons 1 in aromatase 
mRNA
The utilization of multiple exons 1 of the aromatase gene in
breast tissues was investigated by RT-PCR as previously
described [28]. Oligonucleotide primers 1a (5'-CTGGAG-
GGCTGAACACGTGG-3'), specific for placenta-type exon 1
(exon 1a); 1b (5'-GACCAACTGGAGCCTGACAG-3'), spe-Available online http://breast-cancer-research.com/content/11/4/R48
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cific for skin fibroblast/fetal liver-type exon 1 (exon 1b); 1c (5'-
CCTTGTTTTGACTTGTAACCA-3'), specific for ovary-type
exon 1 (exon 1c); and 1d (5'-AACAGGAGCTATAGATGAAC-
3'), specific for ovary/prostate-type exon 1 (exon 1d), and anti-
sense primer 3b (5'-CAGAGATCCAGACTCGCATG-3'),
specific for exon 3, were synthesized.
RNA fractions from breast tissues were reverse-transcribed
with SuperScript II RNase H- Reverse Transcriptase and spe-
cific antisense primer 6a. The resulting cDNAs were amplified
by PCR using fluorescent dye (6-carboxyfluorescein)-labeled
primer 3b and primer 1a, 1b, 1c, or 1d. Fluorescent PCR prod-
ucts were separated by electrophoresis on a 2% agarose gel
and then analyzed with an ABI PRISM 377 DNA Sequencer.
Immunohistochemistry
Representative slides of primary carcinomas were selected for
immunohistochemical examination. Antigen retrieval was per-
formed by boiling the sections for 2 minutes in 10 mM citrate
buffer (pH 6) using a pressure cooker. After the blocking of
nonspecific activity, the sections were incubated with predi-
luted anti-estrogen receptor (anti-ER) mouse monoclonal anti-
body (clone 1D5; Dako, Carpinteria, CA, USA). Incubation
with the anti-ER antibody was for 60 minutes at room temper-
ature. Dako ChemMate Envision (Dako) was used for all immu-
nohistochemical stains. A positive control slide, whose
immunoreactivity had been confirmed, and a negative control
slide, to which subclass-matched control IgGs instead of the
specific monoclonal antibody were applied, were included in
each batch. The results of immunologic staining were
assessed by two pathologists (NHo and KT) independently,
and where discrepancies occurred, the cases were dis-
cussed. Immunoreactivity for ER was scored by evaluating the
percentage of positively stained cancer cells, irrespective of
intensity; nuclear immunoreactivity in 10% or more of the can-
cer cells was considered positive according to St. Gallen Con-
sensus 2003 [30].
Statistics
Statistical analyses were carried out using StatView 5.0 (SAS
Institute Inc., Cary, NC, USA). In regard to aromatase mRNA
levels, one-factor analysis of variance (ANOVA) was used for
the comparison of multiple groups, and the Scheffé test was
used for comparisons between two of the multiple groups. For
comparison of aromatase mRNA levels between mucinous
carcinomas and carcinomas of other histologic types, the Stu-
dent t test was used. Patterns of preferential utilization of mul-
tiple exons 1 of the aromatase gene (or distribution of 'Ex 1
group' as described below) were compared by chi-square test
for independence or Fisher exact test for independence using
a contingency table as follows: EldCa versus EldNorm,
ContCa versus ContNorm, EldCa versus ContCa, and Eld-
Norm versus ContNorm. A P value of less than 0.05 was con-
sidered significant.
Results
Comparison of aromatase mRNA levels among each 
tissue category
Levels of the mean ± standard error of mean of aromatase
mRNA obtained for EldCa, EldNorm, ContCa, and ContNorm
were 19.7 ± 2.97 amol/mgRNA, 8.22 ± 1.91 amol/mgRNA,
9.45 ± 1.75 amol/mgRNA, and 4.26 ± 1.09 amol/mgRNA,
respectively (Table 1 and Figure 1). Aromatase mRNA levels
were significantly different among the four tissue categories
(one-factor ANOVA, P < 0.0001). When cancerous and nor-
mal tissues were compared, EldCa exhibited significantly
higher aromatase levels than did EldNorm (Scheffé test, P =
0.0028), whereas there was no significant difference between
ContCa and ContNorm (P = 0.4477). When the elderly and
controls were compared, EldCa exhibited significantly higher
aromatase levels than did ContCa (P  = 0.0095), whereas
there was no significant difference between EldNorm and
ContNorm (P = 0.6760) (Figure 1).
Comparison of preferential utilization of multiple exons 
1 of the aromatase gene and aromatase mRNA levels 
among EldCa, EldNorm, ContCa, and ContNorm
To determine which types of multiple exons 1 are used, RT-
PCR analysis was carried out, and the relative utilization pref-
erence of exons 1 was fluorometrically determined as shown
in Figure 2. Utilization of multiple exons 1 in each tissue cate-
gory (EldCa, EldNorm, ContCa, and ContNorm) and mean lev-
els of aromatase mRNA according to which exons 1 were
used are summarized in Table 1. In the first column of Table 1,
for example, exon 1d > 1b > 1c is conventionally designated
as dbc. The proportion of cases utilizing exon 1c and/or 1d
was higher in ContCa (26/35 = 74%) than in ContNorm (16/
29 = 55%), although the difference was not significant (chi-
square test for independence, P  = 0.1090). Most of both
EldCa (36/38 = 95%) and EldNorm (30/34 = 88%) utilized
exon 1d, whereas a significantly lower proportion of ContCa
(7/35 = 20%) and ContNorm (2/29 = 7%) utilized exon 1d
(Fisher exact test for independence, EldCa versus ContCa, P
< 0.0001; EldNorm versus ContNorm, P < 0.0001). In both
EldCa and EldNorm, cases that utilized both exon 1c and exon
1d exhibited higher aromatase mRNA levels than those utiliz-
ing either exon 1c or exon 1d. Furthermore, among EldCa and
EldNorm utilizing both exon 1c and exon 1d, all of EldCa exhib-
ited exon 1d > exon 1c, whereas EldNorm exhibited the oppo-
site result. Given the characteristic pattern of exon 1 utilization
among each tissue category and aromatase mRNA levels,
cases were categorized into five groups according to which
exons 1 were utilized (Ex 1 groups): group 'b', which exclu-
sively utilized exon 1b; group 'c', which utilized exon 1c but not
exon 1d; group 'c > d', which utilized both exon 1c and exon
1d with dominance of exon 1c; group 'd', which utilized exon
1d but not exon 1c; and group 'd > c', which utilized both exon
1c and exon 1d with dominance of exon 1d. The presence or
dominance of exon 1b did not affect aromatase mRNA levels
when co-utilized with other exons 1, and grouping was regard-Breast Cancer Research    Vol 11 No 4    Honma et al.
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less of exon 1b; for example, cases showing exon 1d > 1c,
exon 1d > 1c > 1b, exon 1d > 1b > 1c, and exon 1b > 1d >
1c were all categorized into group 'd > c' (Table 1). The distri-
bution of Ex 1 groups was significantly different between
EldCa and EldNorm, between EldCa and ContCa, and
between EldNorm and ContNorm (all P < 0.0001, chi-square
test for independence), whereas there was no significant dif-
ference between ContCa and ContNorm (P = 0.3274) (Figure
1).
Comparison of aromatase mRNA levels according to Ex 
1 groups in each tissue category or according to tissue 
categories in each Ex 1 group
Significant or almost significant differences in aromatase
mRNA levels according to Ex 1 groups were observed in
EldCa (P = 0.0511), EldNorm (P = 0.0444), and ContNorm
(P = 0.0209), whereas no significant difference was obtained
in ContCa (P = 0.4871, one-factor ANOVA) (Table 1). There
was no significant difference of aromatase mRNA levels
according to tissue categories in each Ex 1 group except
group 'b' (group 'd > c', P = 0.8610; group 'd', P = 0.0941;
Table 1
Aromatase mRNA levels and preferential utilization of multiple exons 1 of the aromatase gene
Exon 1 group Tissue category
EldCa EldNorm ContCa ContNorm P valuea
n (%) Aromatase 
mRNA ± 
SEMb
n (%) Aromatase 
mRNA ± 
SEMb
n (%) Aromatase 
mRNA ± 
SEMb
n (%) Aromatase 
mRNA ± 
SEMb
'd > c' 20 (53%) 26.5 ± 4.49 1 (3%) 22.8 0.8610 NS
dc 5 (13%) 35.5 ± 14.4
dcb 1 (3%) 18.8
dbc 7 (18%) 21.8 ± 5.79
bdc 7 (18%) 25.8 ± 5.98 1 (3%) 22.8
'd' 16 (42%) 12.0 ± 3.28 18 (53%) 4.67 ± 1.13 2 (6%) 10.9 ± 7.75 0.0941 NS
d 12 (32%) 13.7 ± 4.21 15 (44%) 4.13 ± 1.30
db 2 (5%) 6.05 ± 0.350 1 (3%) 9.20
bd 2 (5%) 8.25 ± 7.15 2 (6%) 6.45 ± 0.950 2 (6%) 10.9 ± 7.75
'c > d' 12 (35%) 15.3 ± 4.54 4 (11%) 8.56 ± 4.57 2 (7%) 2.98 ± 1.67 0.4445 NS
cd 1 (3%) 10.5 3 (9%) 4.44 ± 2.80 2 (7%) 2.98 ± 1.67
cdb 3 (9%) 11.2 ± 9.32
cbd 5 (15%) 20.5 ± 8.85 1 (3%) 20.9
bcd 3 (9%) 12.6 ± 8.18
'c' 2 (5%) 13.1 ± 11.6 3 (9%) 3.37 ± 2.56 19 (54%) 10.8 ± 2.82 14 (48%) 7.26 ± 1.96 0.5534 NS
c 2 (5%) 13.1 ± 11.6 3 (9%) 3.37 ± 2.56 10 (29%) 9.07 ± 4.34 5 (17%) 2.04 ± 0.645
cb 4 (11%) 17.2 ± 7.01 5 (17%) 9.33 ± 3.54
bc 5 (14%) 9.12 ± 3.30 4 (14%) 11.2 ± 4.26
'b' = b 1 (3%) 1.10 9 (26%) 5.21 ± 1.54 13 (45%) 1.22 ± 0.339 0.0222 S
Total 38 (100%) 19.7 ± 2.97 34 (100%) 8.22 ± 1.91 35 (100%) 9.45 ± 1.75 29 (100%) 4.26 ± 1.09 < 0.0001 S
P valuec 0.0511 NS 0.0444 S 0.4871 NS 0.0209 S
Comparison of aromatase mRNA levels according to preferential utilization of multiple exons 1 of the aromatase gene in carcinomas from the 
elderly (EldCa), normal tissues from the elderly (EldNorm), carcinomas from controls (ContCa), and normal tissues from controls (ContNorm). For 
example, dcb means exon 1d > 1c > 1b. aComparison of aromatase mRNA levels according to tissue categories in each exon 1 group or in total 
(one-factor analysis of variance). bValues are presented in amol/mgRNA. cComparison of aromatase mRNA levels according to exon 1 groups in 
each tissue category (one-factor analysis of variance). NS, not significant; S, significant; SEM, standard error of the mean.Available online http://breast-cancer-research.com/content/11/4/R48
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group 'c > d', P = 0.4445; group 'c', P = 0.5534; group 'b', P
= 0.0222; one-factor ANOVA) (Table 1).
Comparison of estrogen receptor status, aromatase 
mRNA levels, and distribution of Ex 1 groups according 
to histologic types among EldCa
Mean levels of aromatase mRNA were compared according to
histologic types among EldCa (Table 2). Significant difference
of aromatase levels was observed among the four histologic
types (P = 0.0403, one-factor ANOVA). Mucinous carcinomas
exhibited significantly higher levels than the other carcinomas
(39.1 ± 8.99 amol/mgRNA versus 16.8 ± 2.86 amol/mgRNA,
P = 0.0090, Student t test). All five mucinous carcinomas
were ER-positive (Table 2). In regard to the distribution of Ex
1 groups in each histologic type (Table 2), all five mucinous
carcinomas were classified as group 'd > c', showing a ten-
dency to differ from the distribution of the other carcinomas (P
= 0.0750, chi-square test for independence).
Discussion
EldCa, EldNorm, ContCa, and ContNorm each exhibited char-
acteristic features in the usage of multiple exons 1 of the aro-
matase gene. The distribution of Ex 1 groups was significantly
different between EldCa and EldNorm, between EldCa and
ContCa, and between EldNorm and ContNorm (all P  <
0.0001). Mean levels of aromatase mRNA were significantly
different among the four tissue categories (P < 0.0001), pro-
ducing significant differences between EldCa and EldNorm
and between EldCa and ContCa. Aromatase mRNA levels sig-
nificantly or almost significantly differed according to Ex 1
groups in each tissue category except ContCa, whereas no
significant difference of aromatase mRNA levels was observed
according to tissue categories in any Ex 1 group except group
'b'. Those results suggest that differences of aromatase
mRNA levels between tissue categories were related to the
preferential usage of multiple exons 1 in each tissue category
(Figure 1).
Given that exon 1d was used in a significantly larger propor-
tion of elderly tissues than the tissues of the control group
regardless of whether the tissue was cancerous or normal, the
utilization of exon 1d seems to be characteristic of elderly tis-
sue. Contrary to the control group, where exon 1b is preferen-
tially utilized under physiologic conditions, the utilization of
exon 1d seems to be physiologic in the elderly. The specific
utilization pattern of multiple exons 1 in elderly breast tissue
has not been reported elsewhere. This seems to be because
of a difference in subjects as the present study dealt with a
number of tissues in the very elderly, who have been free from
ovarian function for decades and in whom peripherally local-
ized estrogen-metabolizing enzymes are almost the sole
source of estrogens. Among many estrogen-metabolizing
enzymes, aromatase plays a key role in estrogen biosynthesis.
Estrogen is known to be essential to maintain various physio-
logic functions. The decrease of serum estrogens has been
Figure 1
Comparison of aromatase mRNA levels and distribution of Ex 1 groups  among tissue categories Comparison of aromatase mRNA levels and distribution of Ex 1 groups 
among tissue categories. Aromatase mRNA levels (top, Scheffé test) 
and distribution of Ex 1 groups (bottom, chi-square test for independ-
ence) were compared among carcinomas from the elderly (EldCa), nor-
mal tissues from the elderly (EldNorm), carcinomas from controls 
(ContCa), and normal tissues from controls (ContNorm). Bar indicates 
standard error of the mean. *P < 0.01; **P < 0.0001.
Figure 2
Reverse transcription-polymerase chain reaction analysis of usage of  alternative exons 1 of the aromatase gene Reverse transcription-polymerase chain reaction analysis of usage of 
alternative exons 1 of the aromatase gene. An example of a breast can-
cer from elderly patients (EldCa) is shown. Exon 1d is preferentially 
used in the EldCa case, followed by exon 1c and exon 1b (1d > 1c > 
1b, dcb, unbroken line). Broken line indicates size standards.Breast Cancer Research    Vol 11 No 4    Honma et al.
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reported to be related to many geriatric diseases, including
osteoporosis [31], Alzheimer disease [32], and atherosclero-
sis [33]. Although aromatase mRNA levels of EldNorm and
ContNorm did not significantly differ, EldNorm exhibited
almost twice the levels of aromatase mRNA in comparison
with ContNorm. Switching of the preferential use of multiple
exons 1 during aging might be advantageous to peripherally
produce estrogens by increasing aromatase levels (Figure 1).
Given that connective tissue is a major component of normal
breast tissue, it cannot be excluded that such phenomena may
be observed systemically. Several authors have reported that
basal aromatase levels in peripheral stroma are increased in
the elderly [34-36]. A systematic study may elucidate the
physiologic role of aromatase in the elderly.
Contrary to EldNorm, among which more than 30% of cases
were classified as group 'c > d', more than half of cases of
EldCa were classified as group 'd > c'. The precise mecha-
nisms of how exon 1d becomes frequently utilized among eld-
erly tissues and how the dominance of exon 1d and exon 1c is
converted between EldCa and EldNorm are not known at
present. Each exon 1 has its characteristic promoter region
[21]. The promoter of exon 1b, a glucocorticoid-stimulated
promoter, has a characteristic TATA box-less and GC-box
structure, which is often found in the proximal regions of
housekeeping genes, and is regulated by class 1 cytokines,
tumor necrosis factor-alpha, and glucocorticoids. This may be
why transcription from exon 1b does not seem to be so rigid
and is widely found in extragonadal tissues, such as skin
fibroblasts, adipose tissue, and normal breast tissue. The pro-
moters of exons 1c/1d, in contrast, have not only the rigid
structure of CAAT and TATA boxes but also multiple sites of
activator protein-1 and cAMP-responsive element (CRE) in
proximal regions which enable induction of the effective tran-
scription of the aromatase gene in response to various stimu-
lants, such as prostaglandin E2 (PGE2), gonadotropins, or
growth factors, whose second messenger is cAMP or protein
kinase C (PKC) [21]. During senescence, upregulated
cyclooxygenase-2 (COX-2) expression and the resulting
increase in the production of PGE2 in stromal cells, such as
fibroblasts or macrophages, have been reported [37-39].
Interaction between carcinoma cells and surrounding stromal
cells also elevates COX-2 and PGE2 levels [40]. PGE2 may be
one of the key factors to explain the switching mechanism from
exon 1b to exon 1c/1d during aging and carcinogenesis
[22,41]. Gonadotropins may be another candidate to explain
the mechanism. Markedly low serum estrogen levels in elderly
women result in the elevation of gonadotropins, which may
lead to switching to exon 1c/1d through cAMP. cAMP will acti-
vate PKA, which will lead to the binding of CRE binding
(CREB) to CRE in proximal region of exons 1c/1d. Exons 1c/
d are typically utilized in the ovary, where aromatase is induced
in response to gonadotropins [20]. Our preliminary study sug-
gested that the ovary may alternatively utilize exon 1c or 1d
according to the menstrual cycle (unpublished observation).
Changes in hormonal circumstances, such as the ratio of
gonadotropins (follicle-stimulating hormone/lutenizing hor-
mone) during the menstrual cycle, may be somehow associ-
ated with the switching between exon 1c and 1d. In cancerous
tissue, there have been many studies to elucidate the DNA-
binding proteins, transcription factors, and co-regulators that
regulate the alternative utilization of multiple exons 1 [42,43].
For example, S1 (silencer element), which is situated between
exons 1c and 1d, negatively regulates aromatase expression in
normal breast tissue, suppressing the function of exons 1c/1d
in combination with EAR-2/COUP-TF-1/EAR-γ. In cancer tis-
sue, the expression levels of EAR-2/COUP-TF-1/EAR-γ
decreased and aromatase expression is upregulated through
the binding of ERRα-1 (estrogen-related receptor alpha-1) to
S1 [42,43]. Aging and carcinogenesis may somehow affect
the constitution of these DNA-binding proteins, transcription
factors, and co-regulators. Further study is needed to eluci-
Table 2
Estrogen receptor status, aromatase mRNA levels, and exon 1 group of cancer from the elderly according to histologic types
Histologic type (n) Estrogen receptor Aromatase mRNA ± SEM, amol/mgRNA Exon 1 group
+ (%) - d > c d c < d c b
Muc (5) 5 (100%) 0 39.1 ± 8.99 5 0 0 0 0
Others (33) 22 (67%) 11 16.8 ± 2.86 15 16 0 2 0
Apo (7) 0 (0%) 7 20.1 ± 4.06 3 3 0 1 0
ILC (2) 1 (50%) 1 2.45 ± 0.05 1 1 0 0 0
IDC (24) 21 (88%) 3 17.0 ± 3.68 11 12 0 1 0
Total (38) 27 (71%) 11 19.7 ± 2.97 20 16 0 2 0
P value Muc vs. others 0.0090 S 0.0750 NS
+, positive; -, negative; Apo, apocrine carcinoma; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Muc, mucinous carcinoma; NS, 
not significant; S, significant; SEM, standard error of the mean.Available online http://breast-cancer-research.com/content/11/4/R48
Page 7 of 8
(page number not for citation purposes)
date the molecular mechanism of switching of the preferential
use of multiple exons 1 during aging and carcinogenesis.
Among EldCa, mucinous carcinomas examined were all ER-
positive [44,45], were all classified as group 'd > c', and exhib-
ited significantly higher aromatase mRNA levels than other
carcinomas. These findings may suggest the importance of
peripheral aromatase and estrogens in the pathobiology of
mucinous carcinoma, which is a specific histologic type fre-
quently observed in elderly women [24].
Conclusions
This is the first study to systematically examine the preferential
usage of multiple exons 1 of the aromatase gene in breast tis-
sue of the very elderly. Elderly breast tissues typically used
exon 1d irrespective of whether the tissues were cancerous or
normal. The dominance of exon 1c and exon 1d was converted
between cancerous and normal tissues. This seems to at least
partly explain the elevation of aromatase mRNA levels in eld-
erly breast cancer. The molecular mechanism of how switch-
ing of exons 1 occurs should be further studied.
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